DermTech, Inc. (DMTK): Price and Financial Metrics

DermTech, Inc. (DMTK)

Today's Latest Price: $45.48 USD

2.56 (5.96%)

Updated Jan 25 4:00pm

Add DMTK to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 64 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

DMTK Stock Summary

  • The ratio of debt to operating expenses for DermTech Inc is higher than it is for about merely 0.53% of US stocks.
  • DMTK's price/sales ratio is 157.14; that's higher than the P/S ratio of 97.17% of US stocks.
  • In terms of volatility of its share price, DMTK is more volatile than 93.8% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to DermTech Inc are REFR, IGC, ECOR, APYX, and CUTR.
  • Visit DMTK's SEC page to see the company's official filings. To visit the company's web site, go to

DMTK Stock Price Chart Interactive Chart >

Price chart for DMTK

DMTK Price/Volume Stats

Current price $45.48 52-week high $47.08
Prev. close $42.92 52-week low $8.69
Day low $42.02 Volume 1,470,900
Day high $47.08 Avg. volume 1,352,040
50-day MA $22.51 Dividend yield N/A
200-day MA $14.89 Market Cap 891.18M

DermTech, Inc. (DMTK) Company Bio

DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive diagnostic tests to diagnosis skin cancer and related conditions in the United States. The company offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. It also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. The company is also developing non-melanoma skin cancer diagnostic and non-melanoma skin cancer risk assessment products. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.

DMTK Latest News Stream

Event/Time News Detail
Loading, please wait...

DMTK Latest Social Stream

Loading social stream, please wait...

View Full DMTK Social Stream

Latest DMTK News From Around the Web

Below are the latest news stories about DermTech Inc that investors may wish to consider to help them evaluate DMTK as an investment opportunity.

DermTech Chief Scientific Officer Michael Howell Presented at Dermatology Summit 2021

DermTech, Inc. (NASDAQ: DMTK) ("DermTech"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today its presentation at the 2021 Dermatology Summit virtual conference (the "Dermatology Summit") on Jan. 8, 2021. The Dermatology Summit uniquely brings together members of the financial community and business leaders from established and emerging companies in the dermatology space to help foster investment and partnerships in the next generation of dermatology companies and products.

Yahoo | January 19, 2021

DermTech PLA to enrich melanoma positivity nearly five-fold in biopsied lesions

DermTech (DMTK) has published the results of a large registry study finding that the evaluation of genomic atypia using Pigmented Lesion Assay ((PLA)) may be a superior approach to guide treatment decisions and manage pigmented lesions, when compared to visual assessment of pigmented lesions. The study reports that lesions biopsied based...

Seeking Alpha | January 15, 2021

DermTech (DMTK) Investor Presentation - Slideshow

The following slide deck was published by DermTech, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | January 15, 2021

DermTech Announces Inclusion of Non-Invasive Genomic Patch Testing in the National Comprehensive Cancer Network® (NCCN) Cutaneous Melanoma Guidelines

DermTech, Inc. (NASDAQ: DMTK) ("DermTech"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that non-invasive genomic patch testing for melanoma, like DermTech’s Pigmented Lesion Assay ("PLA"), has received a recommendation from the National Comprehensive Cancer Network® ("NCCN"). The recommendation indicates that there is uniform NCCN consensus that the intervention is appropriate. The NCCN Clinical Practice Guidelines in Oncology (the "NCCN Guidelines®") for cutaneous melanoma recognize the use of noninvasive genomic patch testing to help guide biopsy decisions for cutaneous melanoma.

Yahoo | January 12, 2021

DermTech Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

DermTech, Inc. (Nasdaq: DMTK) ("DermTech"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the closing of its previously announced underwritten public offering of 4,872,881 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase up to 635,593 additional shares, at a price to the public of $29.50 per share. DermTech’s aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, were $143.7 million. All of the shares in the offering were sold by DermTech.

Yahoo | January 11, 2021

Read More 'DMTK' Stories Here

DMTK Price Returns

1-mo N/A
3-mo 279.95%
6-mo 325.44%
1-year 216.27%
3-year N/A
5-year N/A
YTD 40.20%
2020 161.61%
2019 -39.28%
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7036 seconds.